Reuters: Regulatory News: Lilly says lung cancer drug increased survival in late-stage trial

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Madesmith Modern handmade. Stories from designers. From our sponsors

Lilly says lung cancer drug increased survival in late-stage trial Aug 13th 2013, 12:31 Tue Aug 13, 2013 8:31am EDT Aug 13 (Reuters) - Eli Lilly and Co said its experimental lung cancer drug increased survival of patients in a late-stage trial, and the company plans to file for a U.S. marketing application before the end of 2014. Lilly shares were up 4 percent in premarket trading. The drug, necitumumab or IMC-11F8, was given to patients with advanced non-small cell lung cancer in combination with already-approved chemotherapy drug gemcitabine and cisplatin, and was compared with chemotherapy alone. "If approved, necitumumab could be the first biologic therapy indicated to treat patients with squamous lung cancer," Richard Gaynor, Lilly's vice president for product development and medical affairs, said in a statement. The company's stock closed at $54.05 on the New York Stock Exchange on Monday.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions